Convaliptic 400

Indication
Anticonvalsant

Pharmaceutical Form
film-coated tablets

Retigabine  400mg
Retigabine acts as a neuronal KCNQ/Kv7 potassium channel opener, a mechanism of action markedly different from that of any current anticonvulsants.
This mechanism of action is similar to that of the chemically-similar flupirtine, which is used mainly for its analgesic properties.

Retigabine is quickly absorbed, and reaches maximum plasma concentrations between half an hour and 2 hours after a single oral dose. It has a moderately high oral bioavailability (50–60%), a high volume of distribution (6.2 L/kg), and a terminal half-life of 8 to 11 hours.

 Retigabine requires thrice-daily dosing due to its short half-life.

Retigabine is metabolized in the liver, by N-glucuronidation and acetylation. The cytochrome P450 system is not involved. Retigabine and its metabolites are excreted almost completely (84%) by the kidneys.

Convaliptic,is indicated as adjunctive treatment of drug-resistant partial onset seizures with or without secondary generalization in patients aged 18 years or older with epilepsy, where other appropriate combinations with other medicinal products have proved inadequate or have not been tolerated.

Convaliptic, must be titrated, according to individual patient response, in order to optimise the balance between efficacy and tolerability.